Reuters logo
a month ago
BRIEF-Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura
July 10, 2017 / 12:57 PM / a month ago

BRIEF-Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura

July 10 (Reuters) - Anthera Pharmaceuticals Inc

* Anthera Pharmaceuticals announces result Phase 3 clinical study of Sollpura will be included in the cystic fibrosis foundation therapeutics development network

* Anthera Pharmaceuticals Inc - ‍topline data are expected at end of 2017 or early 2018, depending on speed of patient enrollment.​

* Anthera - ‍CFF TDN approval may result in additional tdn investigational sites participating in study which could further accelerate patient recruitment in U.S.​

* Says ‍result Phase 3 clinical study of Sollpura approved by CFF TDN protocol review committee​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below